If stable disease after 12 months peptide use, trial 3-month break to see if benefits sustained, resume if progression resumes
November 1, 2024: FDA Issues Warning To Patients Taking Compounded Semaglutide Drugs In October, the FDA issued a letter titled, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. In the letter, the FDA warned people taking compounded versions of GLP-1 drugs for weight loss
Weight loss in the first 4 to 8 weeks on lower titration doses is often minimal and this is expected
Habit tracking, weight log, and message history stay in the Fella app as long as your account is open
The patients included in those studies had liver cirrhosis but had no overt HE compared to patients with liver cirrhosis and only minimal HE
By supporting brain health, reducing cravings, and promoting overall well-being, NAD+ may help individuals achieve and maintain sobriety